← Back

Emergent Biosolutions Inc

Emergent BioSolutions Inc. is a life sciences company that provides preparedness and response solutions for public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers vaccines and therapeutics such as ACAM2000 for smallpox and mpox, ANTHRASIL for inhalational anthrax, BAT for botulism, BioThrax for anthrax, CYFENDUS for post-exposure prophylaxis of anthrax, Ebanga for Ebola, Raxibacumab for anthrax, TEMBEXA for smallpox, and CNJ-016 for smallpox vaccination complications. It also provides NARCAN and KLOXXADO nasal sprays for opioid overdose, and contract development and manufacturing services. Incorporated in 1998, it is headquartered in Gaithersburg, Maryland.

Price · split & dividend adjusted
News & notes moving EBS
EBS▲

Emergent BioSolutions Restructuring Cuts 90 Jobs, Targets $40M Savings

Emergent BioSolutions is undergoing a restructuring that aims for annualized savings of approximately $40M and includes 90 layoffs. The company will shutter two Maryland laboratories, sell an unutilized office building for approximately $6M, and exit a warehouse lease. In a presentation, Emergent said the move would lead to the creation of a new Growth organization that integrates the capabilities of R&D, Business Development, Strategy into one function.
EBS ▲
Seeking Alpha·4dRead more →
EBS▲

Emergent BioSolutions Completes $75 Million Bond Repurchase

Emergent BioSolutions Inc. announced it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, reducing the outstanding balance to approximately $364.7 million. The company deployed about $68 million of cash for the repurchases at an average price of 90.6% of face value. CEO Joe Papa said the move reflects disciplined capital deployment and commitment to prudent balance sheet management amid its multi-year transformation plan. Emergent retains a strong cash position and access to an additional $50 million under its asset-based revolving loan facility, and it will discuss the milestone at upcoming investor conferences in September.
EBS ▲
GlobeNewswire·15dRead more →
EBS▼

Emergent BioSolutions cuts 2026 guidance on naloxone competition

Emergent BioSolutions reported second-quarter revenue of $234.3 million, exceeding its guidance, but slashed its full-year 2026 outlook due to increased competition in the naloxone market. The company recorded a $191.3 million non-cash impairment charge tied to its NARCAN asset group, pushing it to a GAAP net loss of $180.2 million, while adjusted net income rose 134% to $30.9 million. Management announced restructuring actions expected to yield about $40 million in annualized savings, including roughly 90 job cuts, and revised 2026 total revenue guidance to $645 million to $675 million from a prior range of $720 million to $760 million. The company also authorized a $75 million debt repurchase program and reported $145 million in July accounts receivable collections.
EBS ▼
The Motley Fool·37dRead more →
© 2026 MarketDXAsset